A Tennessee Corporation IRS Employer Identification No. 62-1765329 Commission file number 001-33637 Cumberland Pharmaceuticals Inc. is required to file reports pursuant to Section 13 or Section 15(d) of the Act. The aggregate market value of common stock held by non-affiliates as of June 30, 2023 was $12,061,328. The number of shares of the registrant's Common Stock, no par value, outstanding as of March 8, 2024 was 14,176,529. Certain information required in Part III of Form 10-K is incorporated by referen ...

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A. J. Kazimi - Chairman and Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to Cumberland Pharmaceuticals 2023 Financial Report and Company Update. This call is being recorded at Cumberland's request and ...

Cumberland Pharmaceuticals Reports Annual 2023 Financial Results 2023 highlights include expanded FDA approval and new study publications NASHVILLE, TENNESSEE (Tuesday, March 5, 2024) – Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $40 million in 2023 and provided $6 million in cash generated from operations. Cumberland ended the year with $82 million in total assets – inclu ...

Financial Performance - Total net revenues for Q3 2023 were $10.1 million, a decrease of $1.3 million (approximately 11.6%) compared to $11.4 million in Q3 2022[204] - Net revenues for the nine months ended September 30, 2023, were $30.2 million, a decrease of $2.7 million or 8.2% compared to $32.9 million for the same period in 2022[243] - Operating loss for the third quarter of 2023 was $1.9 million, compared to an operating loss of $288,588 for the same period in 2022, reflecting an increase in loss of $1.6 million[234] Revenue Breakdown - Vibativ revenue increased by $0.9 million (approximately 46.0%) to $2.8 million in Q3 2023 from $1.9 million in Q3 2022[204] - Sancuso revenue decreased by $2.0 million (approximately 51.1%) to $1.9 million in Q3 2023 from $4.0 million in Q3 2022[204] - Sancuso revenue for the third quarter of 2023 was $1.9 million, down from $4.0 million in the same quarter of 2022, a decline of 52.5%[237] - Kristalose revenue for the first nine months of 2023 was $12.3 million, an increase of $0.9 million (approximately 7.9%) compared to $11.4 million in the same period of 2022[211] - Vibativ revenue for the first nine months of 2023 was $6.8 million, an increase of $0.8 million (approximately 13.3%) compared to $6.0 million in the same period of 2022[212] - Caldolor revenue for the first nine months of 2023 was $3.3 million, a $0.2 million increase (approximately 6.5%) over 2022[212] Cost and Expenses - Cost of products sold for the first nine months of 2023 was $4.5 million, a decrease of $1.9 million (approximately 29.6%) compared to the same period last year[212] - General and administrative expenses increased to $7.2 million in the first nine months of 2023, compared to $6.7 million in the same period of 2022[213] - Cost of products sold for the third quarter of 2023 was $1.8 million, representing 17.5% of net revenues, an improvement from 19.5% in the same quarter of 2022[238] - Research and development costs for the first nine months of 2023 were $4.6 million, down from $5.3 million in the same period last year, primarily due to a $0.7 million reduction in FDA fees[245] Cash Flow and Financing - Cash provided by operating activities totaled $5.1 million for the nine months ended September 30, 2023, primarily due to non-cash expenses add backs of $4.0 million and a decrease in accounts receivable of $0.9 million[262] - Cash provided by operating activities for the nine months ended September 30, 2022, totaled $4.8 million, driven by non-cash expenses and changes in working capital[218] - Financing activities used cash totaling $5.9 million for the nine months ended September 30, 2023, including $3.3 million for line of credit repayments[250] - The company entered into a new Revolving Credit Loan Agreement with Pinnacle Bank on September 5, 2023, providing up to $25 million, with an initial revolving line of credit of $20 million and a three-year term expiring on October 1, 2026[264] - The interest rate on the new credit facility is based on Benchmark (Term SOFR) plus a spread of 2.75%[264] Strategic Initiatives - Cumberland is pursuing international partnerships to expand its product offerings and has established a network to register and provide medicines outside the U.S.[183] - The company is actively seeking to acquire additional marketed products and late-stage development candidates to enhance its portfolio[188] - The company is working with Nephron to provide interim supplies of a special compounded conivaptan product, expected to be released in Q4 2023[229] Market and Risk Factors - The company is exposed to market risk related to changes in interest rates on cash deposits and the revolving credit facility, with a focus on preserving principal while maximizing interest income[265] - Inflation rates have increased recently, potentially impacting operating costs, particularly in clinical trial and employee-related expenses[42] - The company does not utilize derivative financial instruments to manage exposure to interest rate changes[265] Shareholder Information - The company has a share repurchase program to purchase up to $10 million of its common stock, established in January 2019[257] - The dollar value of shares that may yet be purchased under publicly announced plans or programs is approximately $3.19 million as of September 2023[43] - The company has 14,255,700 shares of common stock outstanding as of November 7, 2023[53] Financial Covenants - The company has a financial covenant requiring the maintenance of a Funded Debt Ratio, determined quarterly[264] - As of September 30, 2023, the company had approximately $53.2 million in federal net operating loss carryforwards, expected to offset income tax obligations in the future[241]

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A. J. Kazimi - Chairman and Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to Cumberland Pharmaceuticals Third Quarter 2023 Company Update and Financial Report. This call is being recorded at Cumberl ...

• National introduction underway, with growing acceptance and demand • Aim to significantly grow Caldolor's sales volume over time with the advantages of this new presentation Statement 2 This presentation contains forward-looking statements concerning our approved products and product development, our technology, our competitors, our intellectual property, our financial condition and our plans for research and development programs that involve risks, uncertainties and assumptions. These statements are base ...

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Molly Aggas - IR A.J. Kazimi - CEO Todd Anthony - VP, Organizational Development John Hamm - CFO Conference Call Participants Operator Good afternoon, and welcome to the Cumberland Pharmaceuticals' Second Quarter 2023 Company Update and Financial Report. This call is being recorded at Cumberland's request and will be archived on the company's website for one year from today's date. I ...

In addition to the other information set forth in this quarterly report, an investor should consider the risk factors included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. Inflation rates have increased recently to levels not seen in decades. If our costs, in particular costs related to clinical trial expenses and/or employee-related expenses, were to become subject to significant inflationary pressures, it may adversely impact our business, operating results and financi ...

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Julia Motis - Senior Account Manager, Dalton Agency A.J. Kazimi - CEO Todd Anthony - VP, Organizational Development John Hamm - CFO Operator Good afternoon, and welcome to Cumberland Pharmaceuticals First Quarter 2023 Company Update and Financial Report. This call is being recorded at Cumberland's request and will be archived on the company's website for 1 year from today's date. I wou ...

Joint Venture Agreement (8) OTHER INCOME Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment received related to RediTrex, do not meet the criteria for accounting ...